drugset / Trial / NCT04443088
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Phase 1
Recruiting
78 enrolled
Shenzhen Ionova Life Sciences Co., Ltd.
Merck Sharp & Dohme LLC · collab
NaSequentialOpen-labelTreatment
Summary
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.
Timeline
- Start
- 2020-06-26
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INV-1120 | Small molecule | — | Oral |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | — |